Belluscura PLC
LSE:BELL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.25
25.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Belluscura PLC
Additional Paid In Capital
Belluscura PLC
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Belluscura PLC
LSE:BELL
|
Additional Paid In Capital
$33.4m
|
CAGR 3-Years
291%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Additional Paid In Capital
$615m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Additional Paid In Capital
$2.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
18%
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Additional Paid In Capital
£7.4m
|
CAGR 3-Years
233%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-22%
|
|
|
Angle PLC
LSE:AGL
|
Additional Paid In Capital
£118.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Additional Paid In Capital
£180.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Belluscura PLC
Glance View
Belluscura Plc engages in the provision of medical devices. The Company’s product, the X-PLO2R, is a lightweight portable oxygen concentrator (POC), which is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company focuses on devices and treatments involving oxygen. The X-PLO2R DX is designed to produce approximately six-liters pulse dose oxygen and approximately two-liters of flow oxygen. The firm is focused on developing the medical devices for treating people who are suffering from chronic lung diseases, such as the chronic obstructive pulmonary disease (COPD), respiratory distress caused by coronavirus disease (COVID-19), and other respiratory disorders.
See Also
What is Belluscura PLC's Additional Paid In Capital?
Additional Paid In Capital
33.4m
USD
Based on the financial report for Dec 31, 2023, Belluscura PLC's Additional Paid In Capital amounts to 33.4m USD.
What is Belluscura PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
59%
Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Belluscura PLC have been 291% over the past three years , 59% over the past five years .
You don't have any saved screeners yet
